Fewer systematic prostate core biopsies in clinical stage T1c prostate cancer leads to biochemical recurrence after brachytherapy as monotherapy.
Yu OzawaSunao NoharaKen NakamuraSeiya HattoriYasuto YagiToru NishiyamaAtsunori YorozuTetsuo MonmaShiro SaitoPublished in: The Prostate (2024)
A low number of prostate core biopsies results in worse BCR-free survival after brachytherapy as monotherapy in patients with cT1c PCa.
Keyphrases
- prostate cancer
- high dose
- radical prostatectomy
- radiation therapy
- combination therapy
- open label
- locally advanced
- acute lymphoblastic leukemia
- ultrasound guided
- computed tomography
- low dose
- image quality
- benign prostatic hyperplasia
- tyrosine kinase
- contrast enhanced
- dual energy
- magnetic resonance imaging
- clinical trial
- magnetic resonance
- rectal cancer
- study protocol
- double blind